Canadian study finds minimal evidence of weaker COVID-19 vaccine responses in people with HIV

Moderna vaccine as a third dose produced especially strong responses

People with undetectable HIV who received SARS-CoV-2 vaccines didn’t experience faster antibody declines than people without HIV after two vaccine doses and had equivalent or better antibody responses compared to a control group after a third dose, especially those who received the Moderna vaccine as their third dose, Canadian researchers report in a pre-print article released before peer review.

The study found no evidence of weaker virus neutralisation nor any evidence of weaker vaccine responses in people with a history of a low CD4 cell count. Most people in this study received the Pfizer or Moderna mRNA vaccines but there was some evidence that the Oxford-AstraZeneca vaccine was associated with weaker responses after the first two doses.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search